Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07493538RecruitingPhase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Minneapolis, MinnesotaAges 2–75 - NCT06179524RecruitingPhase 2
CAR-T-19 for CD19-positive B-ALL in children and young adults
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
TianjinAges Up to 25 years - NCT06774677Recruiting
Studying cell communication in hairy cell leukemia for better care
This study looks at how cells talk to each other in hairy cell leukemia, a rare blood cancer. It aims to find ways to improve patient care. Participants may be asked to give blood or tissue samples for research.
Palermo, PAAges 18 years+ - NCT07483476Recruiting
Cell-free DNA in children with new ALL
This study looks at a special blood test that measures cell-free DNA (tiny pieces of genetic material) in children with acute lymphoblastic leukemia (ALL). It aims to understand how this test might help monitor the disease, and it is for newly diagnosed children who haven't started treatment yet.
ParisAges Up to 18 years - NCT07474051Enrolling by invitation
Long-term follow-up for CAR-T cell therapy patients
This study tracks people who received a specific CAR-T cell therapy made by AvenCell. The goal is to monitor their health over time to better understand long-term effects.
BerlinAges Any age - NCT06781515Recruiting
Hairy cell leukemia disease burden study
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
Bologna, BolognaAges 18 years+ - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT07469592Recruiting
Mindfulness and music therapy for stem cell transplant patients
This trial tests a combined mindfulness and music therapy program delivered through an app or website. It aims to help patients cope with the stress of stem cell transplant for blood cancers like leukemia or lymphoma.
Miami, FloridaAges 18 years+ - NCT07464951RecruitingPhase 1
CART123 cells with or without ruxolitinib for AML
This trial tests a new type of immune cell therapy (CART123) alone or with a drug called ruxolitinib for children and young adults with AML that has come back or not responded to standard treatment. The goal is to see if this combination can help destroy leukemia cells.
Philadelphia, PennsylvaniaAges birth–29 years - NCT06764459Recruiting
Study of FLT3 gene changes in AML patients
This trial looks at people with acute myeloid leukemia (AML) who have a change in a gene called FLT3. It aims to understand how this change affects the disease and how well treatments work.
BolognaAges 18 years+ - NCT07445984Recruiting
Gene testing for blood cancer patients
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
Parma, PRAges 1 year+ - NCT07445438Recruiting
A multi-omics study for blood cancers
This study is testing whether a complete platform that analyzes multiple molecular levels (multi-omics) can be used to better understand and diagnose blood cancers (hematological malignancies). It looks at samples from the blood, bone marrow, and tissues to help with initial diagnosis or when cancer returns after treatment.
Parma, PRAges 2 years+ - NCT06802718RecruitingPhase 3
Interferon-alpha after Chemo for Favorable-Risk AML
This study tests if a medicine called interferon-alpha can help keep leukemia from coming back after initial treatment. It is for people with a favorable-risk type of AML who still have tiny traces of leukemia-related genetic material after finishing their first round of chemo.
Beijing, Beijing MunicipalityAges 18–70 - NCT07429461RecruitingEarly Phase 1
SYNCAR-100 for relapsed B-ALL
This trial tests a new CAR-T cell therapy called SYNCAR-100 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. If you qualify, you would receive an infusion of specially modified immune cells designed to attack and kill leukemia cells.
Hangzhou, ZhejiangAges 18–75 - NCT07405424Recruiting
Spiritual care support for adults with new acute leukemia
This study tests whether adding spiritual care to standard treatment helps adults newly diagnosed with acute leukemia feel better emotionally and spiritually. You may join if you are starting your first hospital treatment for AML or ALL.
Chicago, IllinoisAges 18 years+ - NCT07400029RecruitingPhase 2
Obecabtagene autoleucel for B-cell ALL in remission
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Duarte, CaliforniaAges 40 years+ - NCT05870995RecruitingPhase 2
Chemo plus targeted conditioning for hard-to-treat AML
This trial studies a specific chemotherapy plan (called sequential CLAG-Ven) with a gentler “conditioning” treatment before a transplant or donor-based therapy. It may help people with refractory or quickly relapsing acute myeloid leukemia (AML) who have a suitable family or matched donor and can meet certain organ function and infection rules.
Shanghai, Shanghai MunicipalityAges 16–65 - NCT07392242RecruitingPhase 2
Ivosidenib, azacitidine, and venetoclax for acute myeloid leukemia
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
Basking Ridge, New JerseyAges 60 years+ - NCT05603884RecruitingPhase 2
New treatment plan for older adults with newly diagnosed AML
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Xiamen, FujianAges 60 years+ - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT06834529RecruitingPhase 1/Phase 2
CAR-T cell therapy for returning B-cell leukemia or lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Beijing, Beijing MunicipalityAges 14–75 - NCT07383298Enrolling by invitation
Lower dose of olverembatinib for chronic myeloid leukemia
This study looks at whether lowering the dose of olverembatinib (from 30 or 40 mg to 20 mg every other day) keeps working well for people with chronic myeloid leukemia who have already had a good response. It aims to see if a lower dose can still control the cancer while possibly reducing side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06088888RecruitingPhase 1
TGRX-678 for CML that hasn't responded to other treatments
This study tests a new daily pill called TGRX-678 for people with chronic-phase CML who have not responded well to or cannot tolerate other CML treatments. It aims to see if the drug is safe and if it can help control the leukemia.
Houston, TexasAges 18 years+
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.